4,171 reports of this reaction
12.7% of all LAPATINIB reports
#1 most reported adverse reaction
DIARRHOEA is the #1 most commonly reported adverse reaction for LAPATINIB, manufactured by Novartis Pharmaceuticals Corporation. There are 4,171 FDA adverse event reports linking LAPATINIB to DIARRHOEA. This represents approximately 12.7% of all 32,865 adverse event reports for this drug.
Patients taking LAPATINIB who experience diarrhoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIARRHOEA is a frequently reported adverse event for LAPATINIB, accounting for a significant proportion of all reports.
In addition to diarrhoea, the following adverse reactions have been reported for LAPATINIB:
The following drugs have also been linked to diarrhoea in FDA adverse event reports:
DIARRHOEA has been reported as an adverse event in 4,171 FDA reports for LAPATINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIARRHOEA accounts for approximately 12.7% of all adverse event reports for LAPATINIB, making it one of the most commonly reported side effect.
If you experience diarrhoea while taking LAPATINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.